Literature DB >> 8372941

Extramedullary myeloid cell tumors. An immunohistochemical and morphologic study of 28 cases.

S T Traweek1, D A Arber, H Rappaport, R K Brynes.   

Abstract

In an attempt to correlate the morphologic and immunophenotypic findings in extramedullary myeloid cell tumors (EMT), we studied 28 cases with a large panel of antibodies using paraffin section immunohistochemistry. A previous or concurrent diagnosis of acute myelogenous leukemia or chronic myelogenous leukemia was made in 25 cases. Six EMT were morphologically classified as well differentiated (WD-EMT), 17 as poorly differentiated (PD-EMT), and five as blastic EMT. The WD-EMT were easily recognized morphologically and displayed a relatively mature myeloid phenotype, with elastase, CD15, and CD68 positivity in all cases. On the other hand, the five blastic-EMT displayed no morphologic evidence of myeloid derivation, were completely negative for CD15, and were weakly positive for elastase in only one case. The PD-EMT, with a morphologic appearance that resembles large cell non-Hodgkin's lymphoma, variably expressed CD15 and elastase. CD68 and lysozyme were present in the majority of PD-EMT, with some variability, but were negative in most blastic-EMT. CD45 (LCA) was detected in 75% of all EMT and CD34 was positive in 36%; neither antigen was significantly associated with a specific morphology. CD30 reactivity was not evident in any case, but slight positive staining was seen with CD20 (L26) in one WD-EMT. CD43 (Leu 22) was the only antibody that was positive in 100% of cases; staining was always intense and widespread. Antimyeloperoxidase (MPO) was positive in all cases but two, both with a blastic morphology. We conclude that (a) an immunohistochemical panel including CD20, CD43, CD68, and MPO can successfully identify the vast majority (96%) of EMT in paraffin sections, and (b) there is an association between morphology and phenotype in these lesions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8372941     DOI: 10.1097/00000478-199310000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  40 in total

1.  Granulocytic sarcoma preceding AML M0 and the diagnostic value of CD34.

Authors:  E Astall; H Yarranton; J Arno; R Marcus
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

2.  Isolated pancreatic granulocytic sarcoma: a case report and review of the literature.

Authors:  Xin-Ping Li; Wen-Fang Liu; Shu-Rong Ji; She-Hua Wu; Jian-Jun Sun; Yue-Zu Fan
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

3.  Giant granulocytic sarcoma of the vagina concurrent with acute myeloid leukemia with t(8;21)(q22;q22) translocation.

Authors:  Jun Imagawa; Yuka Harada; Tetsumi Yoshida; Akira Sakai; Naomi Sasaki; Akiro Kimura; Hironori Harada
Journal:  Int J Hematol       Date:  2010-09-10       Impact factor: 2.490

4.  Myeloid Sarcoma: Presenting with Massive Cervical and Inguinal Lymphadenopathy.

Authors:  John C Walsh; Michelle G Arnold; Arash Mohtashamian
Journal:  Head Neck Pathol       Date:  2016-07-09

5.  Myeloid sarcoma occurring in the maxillary gingiva: a case without leukemic manifestations.

Authors:  G Colella; A Tirelli; R Capone; C Rubini; S Guastafierro
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

6.  Presence of myeloid precursor cells in the endometrium of an AML patient: a diagnostic challenge!

Authors:  K Lambein; A Janssens; S Weyers; M Praet; P De Paepe
Journal:  Virchows Arch       Date:  2007-10-31       Impact factor: 4.064

7.  Report of an unusual case: testicular involvement of chronic myeloid leukemia 10 years after the complete response.

Authors:  Cem Nedim Yuceturk; Berat Cem Ozgur; Hasmet Sarici; Pelin Borcek; Onur Telli
Journal:  J Clin Diagn Res       Date:  2014-04-15

8.  The application of molecular analyses for primary granulocytic sarcoma with a specific chromosomal translocation.

Authors:  Naohiro Sekiguchi; Takashi Watanabe; Yukio Kobayashi; Chiho Inokuchi; Sung-Won Kim; Yukiko Yokota; Kazuki Tanimoto; Yoshihiro Matsuno; Kensei Tobinai
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

9.  Granulocytic sarcoma with expression of CD30.

Authors:  M Fickers; P Theunissen
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

10.  Granulocytic sarcoma of the breast without development of bone marrow involvement: a case report.

Authors:  Teresa A Vela-Chávez; Myrna D Arrecillas-Zamora; L Yolanda Quintero-Cuadra; Falko Fend
Journal:  Diagn Pathol       Date:  2009-01-06       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.